** Shares of LTR Pharma rise 7.9% to A$0.755
** The biopharmaceutical firm rose as much as 17.9% earlier in the day, their biggest intraday gain since early November
** Co enters an agreement with Australian pharmaceutical wholesaler Symbion for nation-wide distribution for SPONTAN
** SPONTAN is LTR Pharma's lead product for treatment of erectile dysfunction
** About 1.2 mln shares change hands, compared with 30-day average trading volume of 669,941 shares
** Stock down 13.6% YTD, as of last close
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.